enGene Holdings (ENGN – Research Report), the Real Estate sector company, was revisited by a Wall Street analyst today. Analyst Silvan Tuerkcan from JMP Securities reiterated a Buy rating on the stock and has a $18.00 price target.
Silvan Tuerkcan’s rating is based on several strategic developments and financial strengths of enGene Holdings. The expansion of the LEGEND study to additional sites in Asia and Europe is expected to accelerate enrollment and provide pivotal data readouts by the second half of 2025. This expansion, along with the company’s focus on delivering updates with new insights, suggests a promising trajectory for the trial outcomes, particularly with the inclusion of maintenance dosing in patients.
Financially, enGene Holdings is well-positioned with $272.8 million in cash and marketable securities, providing a financial runway into 2027. This strong financial position supports the company’s ongoing research and development efforts. Additionally, the potential for trial modifications to improve outcomes in the LEGEND study further enhances the positive outlook for enGene Holdings, justifying the Buy rating.
In another report released yesterday, Morgan Stanley also maintained a Buy rating on the stock with a $34.00 price target.